Biotech Sector Settles on Trading Higher After Choppy Morning
The biotech sector was having some trouble settling on a direction earlier in today's trading session, but lately the measures that track the group were firmly in positive territory.
The American Stock Exchange Biotech Index was recently up 3%. The Dow Jones Biotech Index were gaining 1.2%, and the Biotech HOLDRs was also rising 1.2%. The latter two were down earlier in the session.
Applied Biosystems (ABI), a part of Applera, posted earnings of 22 cents a share this morning, a penny below the Thomson Financial/First Call estimate, and 4 cents below last year's same-quarter comparison. Revenue rose 3.5% in the quarter, and the company said it expects a slowdown in capital purchases and currency effects to "restrain revenue growth for the next few quarters" traders seemed keen on the stock today. Shares of Applied Biosystems were climbing 7.5% to $27.42.
Celera Genomics (CRA), the other company operating under the Applera umbrella, reported a wider-than-expected loss of 56 cents a share this morning. Analysts expected a loss of 54 cents a share. Celera, which is moving a large amount of its expenditures to drug discovery and research and away from online information, recently rose 7% to $31.20.Amgen (AMGN), which is posting earnings after the bell, fell 3.7% to $57 today. Chiron (CHIR), which beat earnings estimates by a penny yesterday, also slipped, falling 0.2% to $42. Genome Therapeutics (GENE) was climbing 0.7% to $12.45, and Genzyme General (GENZ) rose 6.3% to $55.42. Shares of Biogen (BGEN) were slipping 0.2% to $52.84.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV